Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NYY8
UPID:
FAKD2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NYY8; Q9NVX6; Q9Y2H7
Background:
FAST kinase domain-containing protein 2, mitochondrial, plays a crucial role in the assembly of the mitochondrial large ribosomal subunit. It is part of a protein-RNA module essential for mitochondrial translation and may influence mitochondrial apoptosis.
Therapeutic significance:
Linked to Combined oxidative phosphorylation deficiency 44, understanding FAST kinase domain-containing protein 2's role could unveil new therapeutic strategies.